Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

OCRELIZUMAB for Relapsing multiple sclerosis: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 6,883 adverse event reports in the FDA FAERS database where OCRELIZUMAB was used for Relapsing multiple sclerosis.

Most Reported Side Effects for OCRELIZUMAB

Side Effect Reports % Deaths Hosp.
Covid-19 11,454 20.4% 322 2,256
Fatigue 5,704 10.2% 20 1,174
Urinary tract infection 3,618 6.4% 52 1,503
Headache 3,036 5.4% 13 660
Multiple sclerosis 2,609 4.6% 28 604
Asthenia 2,509 4.5% 23 879
Nasopharyngitis 2,479 4.4% 7 441
Gait disturbance 2,384 4.2% 18 769
Pneumonia 2,333 4.2% 132 1,254
Pain 2,327 4.1% 11 623
Multiple sclerosis relapse 2,326 4.1% 7 576
Fall 2,209 3.9% 31 973
Off label use 2,198 3.9% 44 629
Infusion related reaction 2,116 3.8% 5 287
Drug ineffective 2,018 3.6% 14 306

Other Indications for OCRELIZUMAB

Relapsing-remitting multiple sclerosis (15,658) Multiple sclerosis (15,501) Product used for unknown indication (10,715) Primary progressive multiple sclerosis (6,156) Secondary progressive multiple sclerosis (1,273) Progressive multiple sclerosis (400) Multiple sclerosis relapse (373) Progressive relapsing multiple sclerosis (123) Neuromyelitis optica spectrum disorder (57) Rheumatoid arthritis (37)

Other Drugs Used for Relapsing multiple sclerosis

OFATUMUMAB (3,705) FINGOLIMOD (851) GLATIRAMER (375) ALEMTUZUMAB (350) SIPONIMOD (194) INTERFERON BETA-1A (192) NATALIZUMAB (140) RITUXIMAB (136) OZANIMOD (127) CLADRIBINE (123)

Related Pages

OCRELIZUMAB Full Profile All Relapsing multiple sclerosis Drugs OCRELIZUMAB Demographics OCRELIZUMAB Timeline